Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach
暂无分享,去创建一个
[1] P. Verweij,et al. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. , 2014, The Journal of antimicrobial chemotherapy.
[2] A. McLachlan,et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. , 2014, The Journal of antimicrobial chemotherapy.
[3] Steven W. Johnson,et al. Recent advances in the treatment of life-threatening, invasive fungal infections , 2013, Expert opinion on pharmacotherapy.
[4] H. Itoh,et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[5] S. Seyedmousavi,et al. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis , 2013, Expert review of anti-infective therapy.
[6] D. Buchheidt,et al. Invasive aspergillosis: new insights into disease, diagnostic and treatment. , 2013, Current pharmaceutical design.
[7] Y. Nishi,et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[8] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[9] M. Hoenigl,et al. Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies , 2013, Antimicrobial Agents and Chemotherapy.
[10] D. Andes. Optimizing antifungal choice and administration , 2013, Current medical research and opinion.
[11] D. Fredricks,et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events , 2013, BMC Infectious Diseases.
[12] H. Koo,et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis , 2013, Pediatric blood & cancer.
[13] M. Kainer,et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. , 2012, The New England journal of medicine.
[14] J. Nagel,et al. Evaluation of the effect of obesity on voriconazole serum concentrations. , 2012, The Journal of antimicrobial chemotherapy.
[15] G. Würthwein,et al. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. , 2012, The Journal of antimicrobial chemotherapy.
[16] M. Kouba,et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience , 2012, Mycoses.
[17] T. Egberts,et al. Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients , 2012, Antimicrobial Agents and Chemotherapy.
[18] P. G. Choe,et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] T. Buclin,et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] A. McLachlan,et al. Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.
[21] S. Klein,et al. A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine , 2012, British journal of clinical pharmacology.
[22] P. Soler-Palacín,et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. , 2012, The Journal of antimicrobial chemotherapy.
[23] J. Pilewski,et al. Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity , 2012, Antimicrobial Agents and Chemotherapy.
[24] Joo-Youn Cho,et al. Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers , 2012, Journal of clinical pharmacology.
[25] W. Hope. Population Pharmacokinetics of Voriconazole in Adults , 2011, Antimicrobial Agents and Chemotherapy.
[26] D. Yim,et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[27] P. Troke,et al. Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients , 2011, Antimicrobial Agents and Chemotherapy.
[28] A. Thiébaut,et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.
[29] N. Venisse,et al. Niveau de preuve du suivi thérapeutique pharmacologique du voriconazole. , 2011 .
[30] W. Haefeli,et al. Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring , 2011, Therapeutic drug monitoring.
[31] G. Meyfroidt,et al. Voriconazole plasma levels in children are highly variable , 2011, European Journal of Clinical Microbiology & Infectious Diseases.
[32] S. Eymard-Duvernay,et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[33] J. Mehta,et al. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring , 2010, Bone Marrow Transplantation.
[34] D. Niederwieser,et al. Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients , 2010, Antimicrobial Agents and Chemotherapy.
[35] S. Markantonis,et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. , 2010, International journal of antimicrobial agents.
[36] P. Chandrasekar,et al. Safety of triazole antifungal drugs in patients with cancer. , 2010, The Journal of antimicrobial chemotherapy.
[37] M. Kurokawa,et al. Monitoring Trough Concentration of Voriconazole Is Important to Ensure Successful Antifungal Therapy and to Avoid Hepatic Damage in Patients with Hematological Disorders. , 2009 .
[38] J. Mehta,et al. Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.
[39] Zeruesenay Desta,et al. Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A , 2008, Antimicrobial Agents and Chemotherapy.
[40] D. Touw,et al. International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations , 2008, Antimicrobial Agents and Chemotherapy.
[41] D. Denning,et al. Voriconazole plasma monitoring , 2008, Archives of Disease in Childhood.
[42] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] L. Gordon,et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.
[45] D. Hillaire‐buys,et al. Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database , 2007, The Annals of pharmacotherapy.
[46] L. Gordon,et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.
[47] D. Schaer,et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.
[48] D. Andes,et al. Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.
[49] J. Mehta,et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.
[50] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[51] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[52] N. Wood,et al. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.
[53] H. Lazarus,et al. Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.
[54] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] M A Kish,et al. Guide to development of practice guidelines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] M. Rinaldi,et al. Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma , 2000, Antimicrobial Agents and Chemotherapy.
[57] J. Balian,et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype , 1996, Clinical pharmacology and therapeutics.
[58] J. Enders,et al. Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.
[59] F. Lemaitre,et al. A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms. , 2013, Drug metabolism and pharmacokinetics.
[60] Yoshiro Saito,et al. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. , 2012, Drug metabolism and pharmacokinetics.
[61] A. Hulin,et al. [Level of evidence for therapeutic drug monitoring of voriconazole]. , 2011, Therapie.
[62] A. McLachlan,et al. Clinical importance of the CYP2C19*17 variant allele for voriconazole. , 2011, British journal of clinical pharmacology.
[63] R. Jelliffe,et al. Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[64] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[65] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.
[66] M. Karthaus. Voriconazole versus amphotericin B for invasive aspergillosis. , 2002, The New England journal of medicine.